September 14, 2011 - LifeVest Showcased at Heart Failure Society Annual Meeting

MEDIA CONTACT:

Diane Egan
ZOLL Medical Corporation
+1 (978) 421-9637
degan@zoll.com

ZOLL LIFEVEST WEARABLE DEFIBRILLATOR TO BE SHOWCASED AT AMERICAN ASSOCIATION OF HEART FAILURE SOCIETY OF AMERICA 2011 ANNUAL MEETING

September 14, 2011─CHELMSFORD, MASS.–ZOLL Medical Corporation (Nasdaq GS: ZOLL), a manufacturer of medical devices and related software solutions, today announced that it will display the LifeVest® Wearable Defibrillator in Booth #2812 at the Heart Failure Society of America (HFSA) Annual Meeting being held from September 18-20 in Boston.

Heart failure is estimated to afflict 5.7 million Americans, and 550,000 new cases are diagnosed each year. Patients diagnosed with heart failure experience sudden cardiac arrest at six to nine times the rate of the general population. The LifeVest Wearable Defibrillator is worn by patients at risk for sudden cardiac arrest (SCA), providing protection during their changing medical condition, and until their permanent risk of SCA is established.

“Patients with heart failure are at high risk of sudden cardiac arrest, especially immediately following an acute event such as hospitalization for heart failure decompensation or myocardial infarction,” said Richard A. Packer, Chief Executive Officer of ZOLL. “The LifeVest is an important therapy in the continuum of care for patients with heart failure, protecting patients during this time of highest risk while they are being optimized on medical therapy.”
The LifeVest is lightweight and easy to wear, allowing patients to return to their activities of daily living, while having the peace of mind that they are protected from SCA. The LifeVest continuously monitors the patient’s heart and, if a life-threatening heart rhythm is detected, the device delivers a treatment shock to restore normal heart rhythm.

The LifeVest is used for a wide range of patient conditions or situations, including following a heart attack, before or after bypass surgery or stent placement, as well as for those with cardiomyopathy or congestive heart failure that places them at particular risk.

The LifeVest is covered by most health plans in the United States, including commercial, state, and federal plans. To date, the LifeVest has been prescribed to more than 45,000 patients.

About ZOLL Medical Corporation


ZOLL Medical Corporation develops and markets medical devices and related software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and monitoring, circulation and CPR feedback, data management, fluid resuscitation, and therapeutic temperature management, ZOLL provides a comprehensive set of technologies that help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and critical care.

A NASDAQ Global Select company and a Forbes 100 Most Trustworthy Company for the past three years, ZOLL develops and manufactures its products in the United States, in California, Colorado, Illinois, Massachusetts, Pennsylvania, and Rhode Island. More than 400 direct sales and service representatives, 1,100 business partners, and 200 independent representatives serve our customers in over 140 countries around the globe. For more information, visit www.zoll.com.

Copyright © 2011 ZOLL Medical Corporation. All rights reserved. LifeVest and ZOLL are trademarks or registered trademarks of ZOLL Medical Corporation in the United States and/or other countries. All trademarks are the property of their respective owners.